http://smallmoleculetechnologies.com/wp-content/uploads/2014/12/Small-Molecule-Technologies-Pinnaclife-background.jpg

Patents

Compositions and Methods for Wound Care
Abstract: The present disclosure relates to compositions for and methods of repairing the stratum corneum, compositions and methods for inhibiting excessive transepidermal water loss, compositions for and methods of treating skin that is distressed or wounded, as a result of a disease or other biological condition or process (as distinguished from wounds resulting from trauma), compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation.
Country Reference # Type Filed Serial # Issued Patent # Status
Canada P10416CA00 DCA 11/23/2011 2,764,060 8/25/2015 2,764,060 ISSUED
Germany P10416DE00 7/24/2017 10792731.1 4/26/2017 602010041887.1 ISSUED
European Patent Convent P10416EP00 DCA 11/23/2011 10792731.1 4/26/2017 2445483 ISSUED
France P10416FR00 7/24/2017 10792731.1 4/26/2017 2445483 ISSUED
United Kingdom P10416GB00 7/24/2017 10792731.1 4/26/2017 2445483 ISSUED
Ireland P10416IE00 7/24/2017 10792731.1 4/26/2017 2445483 ISSUED
Philippines P10416PH00 DCA 3/10/2014 12014501044 Pending
United States P10416US01 FCA 6/25/2010 12/823,567 7/1/2014 8,765,794 ISSUED
United States P10416US02 CIP 3/15/2013 13/832,188 8/5/2014 8,796,315 ISSUED
United States P10416US03 CON 7/11/2014 14/328,843 4/28/2015 9,018,237 ISSUED
Wipo P10416WO00 CEQ 6/25/2010 pct/us10/40008 Nat Phase
Wipo P10416WO02 CEQ 3/10/2014 pct/us14/22490 Nat Phase
Compositions for Anti-inflammatory Antioxidant Effects and Improved Respiratory Functions by Specific Histone Deacetylase Inhibition
Abstract: Compositions comprising LSF compositions and treatment regimens comprising administration of LSF containing compositions are disclosed. Compositions and/or regimens may optionally include the administration of vitamins, minerals, and antioxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, including diseases associated with inflammation and/or oxidative stress, are provided. Various methods for use of the LSF compositions for inhibition of histone deacetylases (HDACs) in various cells, tissues, and/or conditions are also provided.
Country Reference # Type Filed Serial # Issued Patent # Status
Australia P11129AU00 11/29/2016 2015287947 3/18/2018 2015287947 ISSUED
Canada P11129CA00 11/29/2016 2,958,372 Pending
European Patent Convent P11129EP00 11/29/2016 15819066.0 Pending
Philippines P11129PH00 11/29/2016 1-2016-502403 Pending
United States P11129US01 FCA 7/8/2015 14/793,839 1/3/2017 9,532,970 ISSUED
United States P11129US02 11/21/2016 15/357,489 Pending
United States P11129US03 5/22/2018 15/986,013 Pending
Wipo P11129WO00 CEQ 7/8/2015 pct/us15/39483 Pending
Hydroxytyrosol and Oleuropein Compositions for Induction of DNA Damage, Cell Death, and LSD1 Inhibition
Abstract: Compositions comprising hydroxytyrosol-containing formulations and treatment regimens comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regimens may optionally include the administration of vitamins, minerals, and antioxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided.
Country Reference # Type Filed Serial # Issued Patent # Status
Canada P10414CA00 DCA 5/7/2015 2,892,375 Pending
European Patent Convent P10414EP00 DCA 5/7/2015 13858012.1 Pending
Philippines P10414PH00 DCA 5/7/2015 1-2015-501055 8/31/2018 1-2015-501055 ISSUED
United States P10414US02 FCA 11/27/2013 14/091,742 9/29/2015 9,144,555 ISSUED
Wipo P10414WO00 CEQ 11/27/2013 pct/us13/72276 Nat Phase
United States P10414US03 CON 8/11/2015 14/823,028 5/30/2017 9,662,302 ISSUED
United States P10414US04 4/25/2017 15/496,866 3/19/2019 10,231,939 ISSUED
Nutritional Supplements
Abstract: A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 µg hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form for oral administration, the dosage unit form comprising a composition containing about 1 microgram to about 50 milligrams hydroxytyrosol or an ester or salt thereof.
Country Reference # Type Filed Serial # Issued Patent # Status
Canada P10415CA00 DCA 1/15/2012 2,769,819 7/21/2015 2,769,819 ISSUED
Germany P10415DE00 6/29/2018 10808641.4 5/30/2018 602010051005.0 ISSUED
European Patent Convent P10415EP00 DCA 8/10/2010 10808641.4 5/30/2018 2464247 ISSUED
France P10415FR00 6/28/2018 10808641.4 5/30/2018 2464247 ISSUED
United Kingdom P10415GB00 6/29/2018 10808641.4 5/30/2018 2464247 ISSUED
United States P10415US01 FCA 8/10/2010 12/853,908 8/19/2014 8,809,311 ISSUED
United States P10415US02 DIV 7/14/2014 14/330,070 3/22/2016 9,289,401 ISSUED
Wipo P10415WO00 CEQ 8/10/2010 pct/us10/45049 Nat Phase
Olivamine-Induced Improvement in Endothelial Cells Viability and Function
Country Reference # Type Filed Serial # Issued Patent # Status
United States P11429US00 NEW 6/5/2015 14/731,441 Published
Wipo P11429WO00 6/3/2016 PCT/US16/35742 Published